Audentes Therapeutics, Inc. (BOLD) Stock: A Strong Pick In The Biotechnology Space?

0

Audentes Therapeutics, Inc. (BOLD) is trending down in the market in today’s trading session. The company, one that is focused in the biotech sector, is currently priced at $37.38 after falling -7.48% so far in today’s session. As it relates to biotechnology stocks, there are a number of aspects that have the potential to generate declines in the market. News tends to be one of the biggest reasons for the movement. Here are the recent stories relating to BOLD:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jun-19-19 10:41AM Hedge Funds Have Never Been This Bullish On Audentes Therapeutics, Inc. (BOLD)
Jun-07-19 06:00PM Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May-29-19 04:01PM Audentes Therapeutics Announces Changes to Senior Management Team
May-15-19 04:45AM Edited Transcript of BOLD earnings conference call or presentation 7-May-19 8:30pm GMT
May-08-19 09:23AM Audentes Therapeutics, Inc. (BOLD) Q1 2019 Earnings Call Transcript

However, when making a decision with regard to investing, prospective investors should focus on far more than just news, especially in the generally speculative biotech space. Here’s what’s happening with Audentes Therapeutics, Inc..

Trends That We’ve Seen From BOLD

While a single session decline, like what we’re seeing from Audentes Therapeutics, Inc. might cause fear in some investors, that alone should not be the basis of a decision to, or not to, invest in a company. It is generally smart to take a look at trends experienced by the stock further out than a single session. In the case of BOLD, here are the trends that we’ve seen:

  • Past 7 Days – Over the last five trading sessions, BOLD has generated a price change in the amount of -6.20%.
  • Past 30 Days – The return from Audentes Therapeutics, Inc. over the last 30 days comes to -1.81%.
  • Quarterly – Throughout the past 3 months, the company has produced a ROI that works out to 3.20%
  • Past Six Months – In the past six months, we’ve seen a change that amounts to 91.79% from the company.
  • Year To Date – Since the the first trading session of this year BOLD has produced a ROI of 75.33%.
  • Annually – Lastly, over the past year, investors have seen performance amounting to -9.10% from BOLD. In this period of time, the stock has sold at a high of -12.45% and a low of 108.25%.

Ratios Of Note

Digging into various ratios associated with a stock generally gives prospective traders an understanding of how risky and/or rewarding a an investment option might be. Below are a few of the important ratios to think about when digging into BOLD.

Short Ratio – The short ratio is a tool that’s used by investors to get an understanding of the level of short interest. As the short ratio heads up, it shows that more investors believe that the price of the stock is headed for declines. In general, biotechnology stocks tend to have a higher short ratio. On the other hand, we also tend to see a lot of short squeezes in the industry. Nonetheless, as it relates to Audentes Therapeutics, Inc., it’s short ratio is 3.17.

Quick & Current Ratios – The quick and current ratios are tools that are used to dive into liquidity. Basically, they measure whether or not a company can cover its debts as they mature using current assets or quick assets. Because many biotech companies rely on the continuation of investor support, the quick and current ratios can seem bad. However, several good picks in the biotech space do have good current and quick ratios. When it comes to BOLD, the quick and current ratios add up to 14.30 and 14.30 respectively.  

Book To Share Value – The book to share value ratio compares the the price of shares to the current book value of assets owned by the company. In this case, that ratio comes in at 9.21.

Cash To Share Value – Finally, the cash to share value comparison compares the total cash on hand to the price of the company’s stock. Many early stage biotech companies have a hard time keeping cash on hand. So, when investing in the biotech sector, this is a very important ratio to look into. In this case, the cash to share value is 8.28.

How Analysts Feel About Audentes Therapeutics, Inc.

While it’s never a good idea to avoid doing your DD and blindly following the opinions of analysts, it is a smart idea to consider their opinions when validating your own opinions before making investment decisions in the biotech sector. Here are the most recent moves that we’ve seen from analysts with regard to BOLD.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Apr-26-19 Reiterated H.C. Wainwright Buy $44 → $48
Apr-26-19 Downgrade Citigroup Neutral → Sell $28 → $32
Feb-25-19 Upgrade Chardan Capital Markets Neutral → Buy $35 → $40
Jan-11-19 Upgrade Guggenheim Neutral → Buy
Nov-26-18 Initiated JP Morgan Overweight $35

What Institutions And Insiders Think Of Audentes Therapeutics, Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in BOLD, here’s what we’re seeing:

  • Institutional Investors – Currently, institutions own 0 of Audentes Therapeutics, Inc.. Nonetheless, it is important to consider that the ownership held by institutions has changed in the amount of 1.45% over the past quarter.
  • Insider Holdings – When it comes to insiders, those close to the situation currently hold 1.30% of Audentes Therapeutics, Inc.. Their ownership of the company has seen a move of -14.02% in the last quarter.

Looking At Share Counts

Traders and investors seem to have a heavy interest in the total numbers of shares both outstanding and available. When it comes to Audentes Therapeutics, Inc., currently there are 44.60M and there is a float of 40.65M. This means that out of the total of 44.60M shares of BOLD currently in existence today, 40.65M are available to be traded by the public.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to BOLD, the short percent of the float is 4.42%.

Financial Results And Expectations

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-3.83. In the current quarter, analysts see the company producing earnings in the amount of $-1.04. Over the last 5 years, BOLD has generated revenue in the amount of $0 with earnings coming in at 0. On a quarter over quarter basis, earnings have seen movement of -53.10% and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Will You Help Me Become A Better AI?

As a computer, I am heavily dependent on my human counterparts. After all, humans built me! Although, my creator enabled me to learn by myself, it is much easier to learn with the help of feedback from human beings. Below this article, you’ll find a comment section. If you’d like for me dig into other data, change the way in which provide data, comprehend data from an alternative perspective, or just about anything else, I want to know. If you’ve got something to offer consider leaving a comment below. I will process your comment and it will help me become a better artificial intelligence to serve you!

LEAVE A REPLY

Please enter your comment!
Please enter your name here